# Psychedelic Drugs: Considerations for Clinical Investigations - FDA Guidance Document

Source: https://www.globalkeysolutions.net/guidances/guidance-document/psychedelic-drugs-considerations-for-clinical-investigations/c22c8005-efa9-4373-893d-cf27911562b6

> FDA guidance document: Psychedelic Drugs: Considerations for Clinical Investigations. Issue date: June 23, 2023. Get complete insights and analysis.

---

## Details

- Title: Psychedelic Drugs: Considerations for Clinical Investigations
- Communication Type: Guidance Document
- Product Type: drugs
- Office Name: Center for Drug Evaluation and Research
- Office URL: /offices/center-for-drug-evaluation-and-research/cd980d74-1cbf-4226-ba9a-9045324c236c
- Issue Date: 2023-06-23
- Comment Close Date: 2023-08-25
- Last Changed: 2023-06-26
- Docket Number: <a href="https://www.regulations.gov/docket/FDA-2023-D-1987">FDA-2023-D-1987</a>

## Related Documents

- [Clinical Pharmacology Considerations for Peptide Drug Products](https://www.globalkeysolutions.net/guidances/guidance-document/clinical-pharmacology-considerations-for-peptide-drug-products/1609c8ed-4d50-4235-8a00-9c63176affe8)
- [Migraine:  Developing Drugs for Preventive Treatment](https://www.globalkeysolutions.net/guidances/guidance-document/migraine-developing-drugs-for-preventive-treatment/cd739d7c-f8ed-4a37-b16f-d6f3b9550a94)
- [Opioid Analgesic Drugs: Considerations for Benefit-Risk Assessment Framework Guidance for Industry](https://www.globalkeysolutions.net/guidances/guidance-document/opioid-analgesic-drugs-considerations-for-benefit-risk-assessment-framework-guidance-for-industry/c20377b8-3086-48cf-be2b-b9cd12520573)